Published in Ann Surg Oncol on August 01, 2008
Pancreatic metastases from renal cell carcinoma: the state of the art. World J Gastroenterol (2011) 1.46
Transarterial chemoembolization (TACE) with mitomycin C and gemcitabine for liver metastases in breast cancer. Eur Radiol (2009) 1.21
Improvement of survival and prospect of cure in patients with metastatic breast cancer. Breast Cancer (2011) 1.15
Breast cancer liver metastases: US-guided percutaneous radiofrequency ablation--intermediate and long-term survival rates. Radiology (2009) 1.08
The benefits of liver resection for non-colorectal, non-neuroendocrine liver metastases: a systematic review. Langenbecks Arch Surg (2014) 1.00
Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome. Surgery (2012) 0.94
Metastasectomy and surgical resection of the primary tumor in patients with stage IV breast cancer: time for a second look? Ann Surg Oncol (2010) 0.92
The role of liver-directed surgery in patients with hepatic metastasis from primary breast cancer: a multi-institutional analysis. HPB (Oxford) (2016) 0.84
Aggressive treatment for hepatic metastases from breast cancer: results from a single center. World J Surg (2013) 0.82
A comparison of laparoscopic radiofrequency ablation versus systemic therapy alone in the treatment of breast cancer metastasis to the liver. HPB (Oxford) (2013) 0.79
Surgical management of breast cancer liver metastases. HPB (Oxford) (2011) 0.78
Locally ablative treatment of breast cancer liver metastases: identification of factors influencing survival (the Mammary Cancer Microtherapy and Interventional Approaches (MAMMA MIA) study). BMC Cancer (2015) 0.75
Metastatic Liver Disease: Indications for Locoregional Therapy and Supporting Data. Semin Intervent Radiol (2017) 0.75
Follow-up study of liver metastasis from breast cancer treated by proton beam therapy. Mol Clin Oncol (2017) 0.75
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med (2011) 12.45
Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol (2010) 5.01
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer. N Engl J Med (2015) 4.97
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol (2013) 3.87
PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov (2012) 2.89
Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc Natl Acad Sci U S A (2011) 2.18
Resection for hepatocellular carcinoma is a good option in Child-Turcotte-Pugh class A patients with cirrhosis who are eligible for liver transplantation. Liver Transpl (2005) 2.04
Genomic profile of breast cancer: cost-effectiveness analysis from the Spanish National Healthcare System perspective. Expert Rev Pharmacoecon Outcomes Res (2014) 1.99
Intensive loading dose of trastuzumab achieves higher-than-steady-state serum concentrations and is well tolerated. J Clin Oncol (2009) 1.65
Sirolimus Use in Liver Transplant Recipients With Hepatocellular Carcinoma: A Randomized, Multicenter, Open-Label Phase 3 Trial. Transplantation (2016) 1.59
Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study. Oncologist (2013) 1.35
Basic oral health goals for Spain 2015/2020. Int Dent J (2009) 1.11
HER2 testing: current status and future directions. Cancer Treat Rev (2013) 1.09
A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma. BMC Cancer (2010) 1.06
Prognostic factors for disease-free survival in patients with T3-4 or N+ rectal cancer treated with preoperative chemoradiation therapy, surgery, and intraoperative irradiation. Int J Radiat Oncol Biol Phys (2006) 1.05
Right-sided diaphragmatic rupture after blunt trauma. An unusual entity. World J Emerg Surg (2011) 1.05
New approaches in angiogenic targeting for colorectal cancer. World J Gastroenterol (2007) 1.03
Methylthioadenosine (MTA) inhibits melanoma cell proliferation and in vivo tumor growth. BMC Cancer (2010) 0.98
Liver transplantation for malignant diseases: selection and pattern of recurrence. World J Surg (2001) 0.98
Patient outcomes in two steroid-free regimens using tacrolimus monotherapy after daclizumab induction and tacrolimus with mycophenolate mofetil in liver transplantation. Transplantation (2008) 0.96
Rationale for targeting fibroblast growth factor receptor signaling in breast cancer. Breast Cancer Res Treat (2015) 0.93
Evaluating the predictive value of biomarkers for efficacy outcomes in response to pertuzumab- and trastuzumab-based therapy: an exploratory analysis of the TRYPHAENA study. Breast Cancer Res (2014) 0.93
Liver transplantation in HIV-HCV coinfected patients: a case-control study. Transplantation (2007) 0.91
Coverage and factors associated with cervical cancer screening: results from the AFRODITA study: a population-based survey in Spain. J Low Genit Tract Dis (2008) 0.91
Exposure-response analysis of pertuzumab in HER2-positive metastatic breast cancer: absence of effect on QTc prolongation and other ECG parameters. Cancer Chemother Pharmacol (2013) 0.90
Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation. J Hepatol (2005) 0.90
Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer. Onco Targets Ther (2011) 0.89
A prospective randomized trial comparing tacrolimus and steroids with tacrolimus monotherapy in liver transplantation: the impact on recurrence of hepatitis C. Transpl Int (2005) 0.89
Superoxide dismutase prevents development of adenocarcinoma in a rat model of Barrett's esophagus. World J Gastroenterol (2005) 0.88
Single HCC in cirrhotic patients: liver resection or liver transplantation? Long-term outcome according to an intention-to-treat basis. Ann Surg Oncol (2012) 0.88
Outcome of patients following hepatic resection for metastatic cutaneous and ocular melanoma. J Hepatobiliary Pancreat Sci (2011) 0.87
Evolution and management of de novo neoplasm post-liver transplantation: a 20-year experience from a single European centre. Hepatol Int (2010) 0.86
Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors. Cancer Chemother Pharmacol (2014) 0.86
Selective COX-2 inhibition is associated with decreased mucosal damage induced by acid and pepsin in rabbit esophagitis. Inflammation (2003) 0.85
Immunosuppression based on mycophenolate mofetil in stable liver transplanted patients. Int Immunopharmacol (2006) 0.85
Contribution of ADAMTS1 as a tumor suppressor gene in human breast carcinoma. Linking its tumor inhibitory properties to its proteolytic activity on nidogen-1 and nidogen-2. Int J Cancer (2013) 0.84
Optimization of liver transplantation as a treatment of intrahepatic hepatocellular carcinoma recurrence after partial liver resection: experience of a single European series. World J Surg (2010) 0.84
Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study. Clin Colorectal Cancer (2002) 0.83
Our experience in liver transplantation in patients over 65 yr of age. Clin Transplant (2008) 0.83
Changes in portal vein flow after adult living-donor liver transplantation: does it influence postoperative liver function? Liver Transpl (2003) 0.83
Lkb1 loss promotes tumor progression of BRAF(V600E)-induced lung adenomas. PLoS One (2013) 0.82
Neoadjuvant breast cancer treatment as a sensitive setting for trastuzumab biosimilar development and extrapolation. Future Oncol (2015) 0.82
FK506 in the maturation of dendritic cells. Haematologica (2002) 0.82
Early antiviral treatment of hepatitis C virus recurrence after liver transplantation in HIV-infected patients. Antivir Ther (2006) 0.81
Transjugular intrahepatic portosystemic shunt for the treatment of sinusoidal obstruction syndrome in a liver transplant recipient and review of the literature. Liver Transpl (2012) 0.81
Indocyanine green plasma disappearance rate: a new tool for the classification of paediatric patients with acute liver failure. Liver Int (2013) 0.79
Visceral leishmaniasis among liver transplant recipients: an overview. Liver Transpl (2008) 0.79
Successful conversion from twice-daily to once-daily tacrolimus in liver transplantation: observational multicenter study. Clin Transplant (2011) 0.79
Liver biopsy-related infection in liver transplant recipients: A current matter of concern? Liver Transpl (2014) 0.78
Multidisciplinary approach to breast cancer diagnosed during pregnancy: maternal and neonatal outcomes. Breast (2012) 0.78
Combined irinotecan, oxaliplatin and 5-fluorouracil in patients with advanced colorectal cancer. a feasibility pilot study. Oncology (2002) 0.77
Indomethacin but not a selective cyclooxygenase-2 inhibitor inhibits esophageal adenocarcinogenesis in rats. World J Gastroenterol (2012) 0.77
Cost-effectiveness analyses of docetaxel versus paclitaxel once weekly in patients with metastatic breast cancer in progression following anthracycline chemotherapy, in Spain. Clin Transl Oncol (2010) 0.77
Preoperative chemoradiation with oral tegafur within a multidisciplinary therapeutic approach in patients with T3-4 rectal cancer. Int J Radiat Oncol Biol Phys (2005) 0.76
Pregnancy after treatment of breast cancer in young women does not adversely affect the prognosis. Breast (2011) 0.76
Novel treatment options in the management of metastatic breast cancer. Clin Adv Hematol Oncol (2011) 0.76
Controlling the structural and electrical properties of diacid oligo(phenylene ethynylene) Langmuir-Blodgett films. Chemistry (2013) 0.76
Does pre-liver transplant HBV DNA level affect HBV recurrence or survival in liver transplant recipients receiving HBIg and nucleos(t)ide analogues? Ann Hepatol (2011) 0.75
Do we need biomarkers to predict the benefit of adding adjuvant taxanes for treatment of breast cancer? Breast Cancer Res (2012) 0.75
In response: Genomic profile of breast cancer. Expert Rev Pharmacoecon Outcomes Res (2015) 0.75
Reply to A. Ocana et al. J Clin Oncol (2013) 0.75
Prognostic and predictive factors and genetic analysis of early breast cancer. Clin Transl Oncol (2009) 0.75
Current situation: lower genital tract pathology and colposcopy training in spanish gynecology and obstetrics residents. J Low Genit Tract Dis (2013) 0.75
ERRATUM: Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity. Sci Rep (2015) 0.75
Xanthine oxidoreductase and preservation injury in human liver transplantation. Transplantation (2004) 0.75
Javier Cortés, MD, on the CLEOPATRA Trial. Oncology (Williston Park) (2015) 0.75
Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile. Curr Cancer Drug Targets (2016) 0.75
Etiology and mortality of spontaneous bacterial peritonitis in liver transplant recipients: a cohort study. Liver Transpl (2014) 0.75
[Hepatic angiomyolipoma in two patients infected with hepatitis C virus]. Gastroenterol Hepatol (2007) 0.75
[Therapeutic management of juxtapapillary duodenal diverticulum]. Cir Esp (2012) 0.75
Low plasma levels of antithrombin III in the early post-operative period following pediatric liver transplantation: should they be replaced? A single-center pilot study. Pediatr Transplant (2014) 0.75
Complete pathological remission in a patient with hormone-receptor positive and c-erbB-2 expression-negative breast cancer treated with FAC chemotherapy during pregnancy. Tumori (2010) 0.75
Safety of liver transplantation with Chagas disease-seropositive donors for seronegative recipients. Liver Transpl (2011) 0.75
Applicability of liver transplantation in Catalonia at the end of the millennium. A prospective study of adult patient selection for liver transplantation. Transpl Int (2003) 0.75
Overexpression of Yes Associated Protein 1, an Independent Prognostic Marker in Patients With Pancreatic Ductal Adenocarcinoma, Correlated With Liver Metastasis and Poor Prognosis. Pancreas (2017) 0.75
Bevacizumab in advanced breast cancer: a new model for the assessment of activity in non-first-line treatment regimens. Anticancer Drugs (2013) 0.75